April 17, 2024 |
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.
The paper is titled ‘Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma’ and was published in Clinical Genitourinary Cancer. It explores the impact of FGFR mutations on response to different first-line anti-tumor regimens treating locally advanced or metastatic urothelial carcinoma. A total of 104 physicians treating first-line locally advanced or metastatic patients with systemic therapy contributed a total of 414 eligible patient records for the real-world evidence study. Findings showed that although FGFR mutations did not impact the overall progression free survival relative to wild type FGFR patients, the subset of gene mutation patients who received first-line immune checkpoint inhibitors without chemotherapy had significantly higher rates of progression relative to wild type patients receiving immune checkpoint inhibitors without chemotherapy.
For this project, Research Partnership was responsible for the survey design, enrolling respondents via fieldwork partners, performing analysis, both internally and with an external statistical analysis partner, as well as reading and approving drafts of the manuscript. We were privileged to assist our partners as they work to better understand responses to anti-tumor therapy in this malignancy and help oncologists refine the optimal treatment for patients.
This content was provided by Inizio
Latest Content from Inizio
Our client wanted to understand why uptake of HPV vaccination in the Asia-Pacific region was limited. In order to help increase uptake, they wanted to publish the market research findings…
Reflections on THET Conference 2016: Evidence, Effectiveness & Impact
Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 patients, including…
Evolution from man to machine
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Therapy Watch SCCHN is part of a wider portfolio…
Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines….
Organising a company’s presence, not just logistically, but in terms of delivering key information, data and messages, is a massive part of some people’s workload at this time of year….
Two clients were co-developing a product and needed to understand the patient journey in two areas of oncology, in order to identify the leverage points where they could provide an…
What steps should pharma and medical device companies take to ensure they get their pricing strategy right in self-pay markets?
As part of our continued growth, we are delighted to announce a new intake of 17 Research Analysts and 5 Fieldwork Project Coordinators into our annual market research graduate programme.http://www.researchpartnership.com/news/2016/09/new-graduates-2016/
